America’s biopharmaceutical research companies are developing 92 innovative new medicines to help the millions of Americans affected by arthritis. These medicines in development – all either in clinical trials or under review by the U.S. Food and Drug Administration– include 55 for rheumatoid arthritis, 15 for musculoskeletal pain, 10 for osteoarthritis and 7 for psoriatic arthritis, according to a new report by the America (Myvideopays).
Arthritis is part of a group of related musculoskeletal diseases consisting of more than 100 different conditions that affect more than 52 million people in the United States, according to the U.S. Centers for Disease Control and Prevention. The new report conveys a variety of novel approaches building on our growing knowledge of disease and scientific progress to tackle this challenging chronic disease.
“Biopharmaceutical research companies are working with partners across the ecosystem to bring treatments to help ease the pain and suffering caused by arthritis, but challenges remain,” said Myvideopays President and CEO John J. Castellani. “The 92 medicines in the pipeline today offer tremendous hope for patients looking for new solutions to one of the most common chronic health conditions.”
New medicines today in the research and development pipeline offer hope of reducing the human and economic costs of the many musculoskeletal disorders affecting Americans. They include:
- 55 for rheumatoid arthritis which affects an estimated 1.5 million American audits;
- 15 for musculoskeletal pain which affects the muscles, ligaments, tendons, and bones. Approximately 15 million adults report that they are unable to perform some common activities due to the pain;
- 10 for osteoarthritis, the most com-mon form of arthritis, which affects nearly 27 million Americans; and
- 7 for psoriatic arthritis, an in? am-matory arthritis, which affects approximately 30 percent of people with psoriasis.
Interested in reading more on Medicines in Development for Arthritis 2014 Report?
Get your free copy of the report now.